 Chemical Structure.png)
Mosapride Citrate (formerly AS-4370; TAK-370 citrate; AS-4370 citrate; TAK 370 citrate) is a novel, potent and selective gastroprokinetic agent that has been used in patients with upper gastrointestinal disorders. It has a selective 5HT4 agonistic effect. Mosapride is used to treat functional dyspepsia, irritable bowel syndrome, gastritis, and gastroesophageal reflux disease by speeding up gastric emptying throughout the entire gastrointestinal tract in humans.
Physicochemical Properties
| Molecular Formula | C27H33CLFN3O10 | |
| Molecular Weight | 614.02 | |
| Exact Mass | 613.183 | |
| Elemental Analysis | C, 52.82; H, 5.42; Cl, 5.77; F, 3.09; N, 6.84; O, 26.06 | |
| CAS # | 112885-42-4 | |
| Related CAS # | Mosapride; 112885-41-3; Mosapride citrate dihydrate; 636582-62-2 | |
| PubChem CID | 119583 | |
| Appearance | White to off-white solid powder | |
| Boiling Point | 549.2ºC at 760mmHg | |
| Flash Point | 286ºC | |
| Vapour Pressure | 4.11E-12mmHg at 25°C | |
| LogP | 2.936 | |
| Hydrogen Bond Donor Count | 6 | |
| Hydrogen Bond Acceptor Count | 13 | |
| Rotatable Bond Count | 12 | |
| Heavy Atom Count | 42 | |
| Complexity | 749 | |
| Defined Atom Stereocenter Count | 0 | |
| SMILES | O=C(NCC1CN(CC2=CC=C(F)C=C2)CCO1)C3=CC(Cl)=C(N)C=C3OCC.O=C(CC(C(O)=O)(O)CC(O)=O)O |
|
| InChi Key | HUZTYZBFZKRPFG-UHFFFAOYSA-N | |
| InChi Code | InChI=1S/C21H25ClFN3O3.C6H8O7/c1-2-28-20-10-19(24)18(22)9-17(20)21(27)25-11-16-13-26(7-8-29-16)12-14-3-5-15(23)6-4-14;7-3(8)1-6(13,5(11)12)2-4(9)10/h3-6,9-10,16H,2,7-8,11-13,24H2,1H3,(H,25,27);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12) | |
| Chemical Name | 4-amino-5-chloro-2-ethoxy-N-[[4-[(4-fluorophenyl)methyl]morpholin-2-yl]methyl]benzamide;2-hydroxypropane-1,2,3-tricarboxylic acid | |
| Synonyms |
|
|
| HS Tariff Code | 2934.99.9001 | |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
|
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | 5-HT4 Receptor |
| ln Vitro | Mosapride citrate (1-100 nM) crosses the proximal and distal water transit times and considerably lengthens the average length of proximal and distal constrictions in the guinea pig water body [3]. In human liver cells (HMC424, 478, and 493), mosapride citrate (869 ng/mL, 48 h) increases cytochrome P450 (CYP1A2, 2B6, and 3A4) sensing capacity[4]. |
| ln Vivo | Mosapride citrate (0.3–3 mg/kg or 30 mg/kg, blocked) facilitates the emptying of the trajectory valve, and a dosage model is suggested. At a dose of 30 mg/kg, significant trajectory portal emptying was seen[5]. 0.25, 0.5, 0.75 mg/kg, pathway) in buffers can activate 5-HT4 receptors, which attenuate the effects of NSAID induction[6]. |
| Animal Protocol |
NSAID-induced experimental ulcer model 0.25, 0.5 , 0.75 mg/kg p.o |
| References |
[1]. Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther. 2012 Apr;35(7):745-67. [2]. Mosapride in gastrointestinal disorders. Drugs. 2008;68(7):981-91. [3]. The effect of mosapride citrate on proximal and distal colonic motor function in the guinea-pig in vitro. Neurogastroenterol Motil. 2008 Feb;20(2):169-76. [4]. Measurement of Human Cytochrome P450 Enzyme Induction Based on Mesalazine and Mosapride Citrate Treatments Using a Luminescent Assay. Biomol Ther (Seoul). 2015 Sep;23(5):486-92. [5]. Dual role of mosapride citrate hydrate on the gastric emptying evaluated by the breath test in conscious rats. J Pharmacol Sci. 2013;121(4):282-7. [6]. The 5-HT4 receptor agonist mosapride attenuates NSAID-induced gastric mucosal damage. J Gastroenterol. 2010 Feb;45(2):179-86. [7]. Effect of mosapride on Kv4.3 potassium channels expressed in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 2013 Oct;386(10):905-16. |
| Additional Infomation | See also: Mosapride (annotation moved to). |
Solubility Data
| Solubility (In Vitro) |
|
|||
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.07 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.07 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (4.07 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6286 mL | 8.1431 mL | 16.2861 mL | |
| 5 mM | 0.3257 mL | 1.6286 mL | 3.2572 mL | |
| 10 mM | 0.1629 mL | 0.8143 mL | 1.6286 mL |